BQ-610 is a highly selective ETAR (ETA receptor) antagonist (IC50= 20 nM) which attenuates ET-induced reduction in cardiac output. It also inhibits ET-1- and ET-3-induced activation of adenylate cyclase (IC50= 28.2 nM). BQ-610 is 30-fold more potent than BQ-123, in porcine aortic smooth muscle membrane assay.
1. Han, H., et al., 1995. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart-attenuation of ischemic injury by the endothelin-1 antagonists BQ123 and BQ610. Journal of molecular and cellular cardiology. 27(2): 761-6. PMID: 7776381
2. Illing, B., et al., 1996. Protective effect of the specific endothelin-1 antagonist BQ610 on mechanical function and energy metabolism during ischemia/reperfusion injury in isolated perfused rat hearts. Journal of cardiovascular pharmacology. 27(4): 487-94. PMID: 8847864
3. Carratu, P., et al., 1997. ET-1 induces mitogenesis in ovine airway smooth muscle cells via ETA and ETB receptors. The American journal of physiology. 272(5 Pt 1): L1021-4. PMID: 9176269
4. Beyer, M E., et al., 1999. Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610. Hypertension. 33(1): 145-52. PMID: 9931095
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.